Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 4/20 | 0.48 |
| ▸ | F2 | P00734 | 2/20 | 0.47 |
| ▸ | F10 | P00742 | 2/20 | 0.47 |
| ▸ | DCTPP1 | Q9H773 | 3/20 | 0.47 |
| ▸ | TNF | P01375 | 1/20 | 0.45 |
| ▸ | PTAFR | P25105 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16372380 | 0.88 | DCTPP1 (0.51) | BRD4DCTPP1TNFKDM4EMEN1 | |
| SCHEMBL31497731 | 0.87 | BRD4 (0.47) | BRD4F2F10DCTPP1TNF | |
| SCHEMBL31513743 | 0.86 | F2 (0.46) | BRD4F2F10DCTPP1TNF | |
| SCHEMBL30501981 | 0.84 | BRD4 (0.48) | BRD4F2F10DCTPP1TNF | |
| SCHEMBL30645297 | 0.83 | TSHR (0.49) | F10DCTPP1TNFKDM4EALDH1A1 | |
| SCHEMBL16372085 | 0.83 | TSHR (0.49) | F10DCTPP1TNFKDM4EALDH1A1 | |
| SCHEMBL31517099 | 0.81 | F2 (0.44) | BRD4F2F10DCTPP1TNF | |
| SCHEMBL30472325 | 0.80 | SRC (0.39) | BRD4F2F10ALDH1A1GAA | |
| SCHEMBL4663206 | 0.80 | ALPL (0.34) | BRD4F2F10DCTPP1KDM4E | |
| SCHEMBL25647219 | 0.76 | ALPL (0.36) | BRD4F2F10KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116253685-B | Preparation method of tergolian prazan intermediate | 成都安满生物医药科技有限公司 | 2024-12-10 | — | — | CN | claimed |
| CN-115108994-B | Tergolian intermediate and preparation method and application thereof | 江苏威奇达药业有限公司 | 2024-05-31 | — | — | CN | claimed |
| CN-115108994-A | Tegolrazan intermediate and preparation method and application thereof | 江苏威奇达药业有限公司 | 2022-09-27 | — | — | CN | claimed |
| US-9493425-B2 | Method for preparation of benzimidazole derivatives | CJ HEALTHCARE CORPORATION (KR) | 2016-11-15 | — | — | US | claimed |
| US-20160159747-A1 | METHOD FOR PREPARATION OF BENZIMIDAZOLE DERIVATIVES | HK INNO.N CORPORATION (KR) | 2016-06-09 | — | — | US | claimed |
| WO-2015005615-A1 | METHOD FOR PREPARATION OF BENZIMIDAZOLE DERIVATIVES | CJ HEALTHCARE CORPORATION (KR) | 2015-01-15 | — | — | WO | claimed |
| CN-122029159-A | Preparation scheme of benzimidazole compound | 拉夸里亚创药株式会社 | 2026-05-12 | — | — | CN | disclosed |
| CN-120483968-A | Tegora method for preparing raw materials | 福安药业集团宁波天衡制药有限公司 | 2025-08-15 | — | — | CN | disclosed |
| WO-2025095097-A1 | Process for producing benzimidazole compound | RAQUALIA PHARMA INC. (JP) | 2025-05-08 | — | — | WO | disclosed |
| CN-116253685-B | Preparation method of tergolian prazan intermediate | 成都安满生物医药科技有限公司 | 2024-12-10 | — | — | CN | disclosed |
| CN-115108994-B | Tergolian intermediate and preparation method and application thereof | 江苏威奇达药业有限公司 | 2024-05-31 | — | — | CN | disclosed |
| CN-116253685-A | Preparation method of tergolian prazan intermediate | 成都安满生物医药科技有限公司 | 2023-06-13 | — | — | CN | disclosed |
| CN-115108994-A | Tegolrazan intermediate and preparation method and application thereof | 江苏威奇达药业有限公司 | 2022-09-27 | — | — | CN | disclosed |
| US-9493425-B2 | Method for preparation of benzimidazole derivatives | CJ HEALTHCARE CORPORATION (KR) | 2016-11-15 | — | — | US | disclosed |
| US-20160159747-A1 | METHOD FOR PREPARATION OF BENZIMIDAZOLE DERIVATIVES | HK INNO.N CORPORATION (KR) | 2016-06-09 | — | — | US | disclosed |
| WO-2015005615-A1 | METHOD FOR PREPARATION OF BENZIMIDAZOLE DERIVATIVES | CJ HEALTHCARE CORPORATION (KR) | 2015-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159747-A1 | METHOD FOR PREPARATION OF BENZIMIDAZOLE DERIVATIVES | CYP3A5, CYP3A4, CYP3A7 | BRD4 23/4885F2 3136/4885F10 3239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.